O Shaughnessy Asset Management LLC Raises Holdings in argenx SE (NASDAQ:ARGX)

O Shaughnessy Asset Management LLC increased its position in argenx SE (NASDAQ:ARGX - Free Report) by 44.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,138 shares of the company's stock after purchasing an additional 969 shares during the period. O Shaughnessy Asset Management LLC's holdings in argenx were worth $1,930,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the 4th quarter valued at about $37,000. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after purchasing an additional 33 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after acquiring an additional 21 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

argenx Price Performance

NASDAQ:ARGX traded down $16.48 during trading hours on Thursday, reaching $547.66. 148,198 shares of the company traded hands, compared to its average volume of 302,623. The firm's 50-day moving average is $611.51 and its 200-day moving average is $603.50. The stock has a market cap of $33.28 billion, a P/E ratio of -622.27 and a beta of 0.60. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. As a group, research analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. JMP Securities upped their price objective on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. William Blair reaffirmed an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Guggenheim increased their target price on argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and set a $720.00 target price on shares of argenx in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.